Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Lapatinib in Early-Stage HER2-Overexpressing Breast Cancer
2005-005186-10Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Adjuvant lapatinib with Adjuvant placebo (2 arms). Primary endpoint: Disease-free survival. Started Jun 2006; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005186-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005186-10.